Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park(Sungkyunkwan University), Eng-Huat Tan(National Cancer Centre Singapore), Kenneth J. O’Byrne(Princess Alexandra Hospital), Li Zhang(Sun Yat-sen University Cancer Center), Michael Boyer(Chris O’Brien Lifehouse), Tony Mok(Chinese University of Hong Kong), Vera Hirsh(McGill University), James Chih‐Hsin Yang(National Taiwan University Hospital), Ki Hyeong Lee(Chungbuk National University Hospital), Shun Lü(Shanghai Chest Hospital), Yuankai Shi(Peking Union Medical College Hospital), Sang-We Kim(Asan Medical Center), Janessa Laskin(BC Cancer Agency), Dong‐Wan Kim(Seoul National University Hospital), Catherine Dubos Arvis(Centre François Baclesse), Karl Kölbeck(Karolinska University Hospital), Scott A. Laurie(Ottawa Hospital), Chun-Ming Tsai(National Yang Ming Chiao Tung University), Mehdi Shahidi(Boehringer Ingelheim (United Kingdom)), Miyoung Kim(Boehringer Ingelheim (Germany)), Dan Massey(Boehringer Ingelheim (United Kingdom)), Victoria Zazulina(Boehringer Ingelheim (United Kingdom)), Luis Paz‐Ares(Hospital Universitario 12 De Octubre)
Cited by 1,171
Abstract
Related Papers
No related papers found
Powered by citation graph analysis